Exime prostatic stent in acute and chronic urinary retention

Area of Science:

• Urology
• Medical Devices
• Prostate Health

Background:

• Urinary retention due to benign prostatic obstruction (BPO) often requires management with indwelling urethral catheters (IUCs).
• The Exime prostatic stent is a silicone-based device designed for temporary urinary retention management, enabling spontaneous voiding.

Purpose of the Study:

• To compare the efficacy and safety of the Exime prostatic stent versus IUCs in patients with urinary retention secondary to BPO.
• To evaluate the Exime stent's effectiveness in restoring urinary flow and assess secondary endpoints like complications and patient preferences.

Main Methods:

• Retrospective study of 43 patients with failed trial without catheter (TWOC) following acute urinary retention (AUR) due to BPO.
• Inclusion criteria: prostate volume ≤120 mL, intravesical prostatic protrusion <5 mm.
• Exime stent insertion performed under local anesthesia as an outpatient procedure.

Main Results:

• Successful stent insertion in 98% of patients, with all achieving spontaneous voiding.
• The Exime stent significantly reduced symptomatic urinary tract infections (9% vs. 40%), bladder spasms (16% vs. 84%), and urinary leakage (0% vs. 30%) compared to IUCs.
• Patients reported significantly lower pain (VAS 2 vs. 8) and higher satisfaction (VAS 8 vs. 1) with the Exime stent.

Conclusions:

• The Exime prostatic stent is an effective treatment for urinary retention in patients with BPO.
• The Exime stent offers a favorable safety profile with fewer complications than IUCs.
• Patient-reported outcomes, including satisfaction and pain, are significantly improved with the Exime stent compared to IUCs.